Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1025 | Thyroid (non-cancer) | ECE2015

Mimic the symptoms of thyroid disorders in pregnant women

Nazarpour Sima , Tehrani Fahimeh Ramezani , Simbar Masoumeh , Tohidi Maryam , Azizi Fereidoun , Majd Hamid Alavi

Introduction: The prevalence of these disorders in pregnant women is relatively high and may affect mother and foetus adversely if they are not evaluated and treated appropriately. Therefore, their diagnosis and treatment is very important. On the other signs and symptoms of thyroid disease can often be masked by the physiologic changes of pregnancy and are not found. The aim of this study was to evaluate the physiological symptoms similar to thyroid disorders and their incide...

ea0037ep138 | Reproduction, endocrine disruptors and signalling | ECE2015

Study on the correlation between serum androgens and sexual function in post-menopausal women

Nazarpour Soheila , Simbar Masome , Tehrani Fahimeh Ramezani , Tohidi Maryam , Majd Hamid Alavi

Introduction: Sexual dysfunction could be under the influence of menopause and the changes it causes in hormone levels. The purpose of this study is to examine the correlation between serum levels of androgens and sexual function in post-menopausal women.Methods: This is a community-based, descriptive-analytical study involving 405 post-menopausal women, aged 40–65 years, who had reached menopause up to 3 years prior to the study. A multi-stage, ran...

ea0070aep1061 | Hot topics (including COVID-19) | ECE2020

The first case report of Pembrolizumab inducing thyroiditis and hypophysitis

Abdel Rahman Maraqa Sima , McMahon Robert , Pinjala Anusha , Arce Gastelum Alheli , Zena Mohsen

Pembrolizumab is a monoclonal antibody (ab) that exerts antineoplastic effects by inhibiting the immunoevasive effects PD-1 grants cancer cells. It’s used to treat several forms of cancer, including melanoma and non-small cell lung cancer. Despite the promise pembrolizumab has demonstrated, it has been associated with immune-related adverse events. In this report, we describe the first case of both thyroiditis and hypophysitis occurring during active pembrolizumab t...

ea0016p426 | Neuroendocrinology | ECE2008

Enos, P22phox and apoE gene polymorphism associations with circulating hormone levels in the elderly

Ianas Olga , Manda Dana , Heltianu Constantina , Sima Anca , Raicu Monica , Covic Marcela , Dumitrache Constantin

Objective: The aim of this study was the identification of eNOS (G894T), p22phox (−930 A/G) and apoE gene polymorphisms associated with the impact of age-dependent endocrine changes.Subjects and methods: Subjects, both genders, were recruited and classified into the three groups: (1) 100 subjects aged 55–80+ years with mild cognitive impairment (MCI) (MMSE<28); (2) 165 age-matched subjects without cognitive impairment (MMSE>...

ea0035p204 | Cardiovascular Endocrinology &amp; Lipid Metabolism | ECE2014

eNOS, p22 phox, CETP and ERα gene polymorphisms related to metabolic–endocrine parameters in postmenopausal women with metabolic syndrome: a population based study

Ianas Olga , Manda Dana , Vladoiu Susana , Popa Oana , Rosca Roxana , Oros Sabina , Covic Marcela , Heltianu Constantina , Sima Anca , Savu Lorand , Giurcaneanu Mihaela

Objective: We previously found an association between eNOS(G894T) polymorphism and components of metabolic syndrome (MetS); thus, we investigated the metabolic–endocrine changes in postmenopausal women with incipient MetS and the interaction with the polymorphisms of eNOS-G894T, p22phox-930 A/G, CETP TaqIB and ESR1 (PvuII and XbaI) genes.Methods: postmenopausal women aged between 60 and 80 years from a population-based study were classified into the...

ea0070ep363 | Pituitary and Neuroendocrinology | ECE2020

Metastatic neuroendocrine tumor of unknown primary site with associated carcinoid syndrome in a young patient–a case report

Antonia Sima , Iulia Florentina Burcea , Mădălina Cristina Sorohan , Roxana Dușceac , Cătălina Poiană

Background: Neuroendocrine tumors (NETs) are relatively uncommon, accounting for 10 to 14 percent of all neuroendocrine neoplasms. Twelve percent to 22% of patiens are metastatic at presentation. The most frequent primary sites are the gastrointestinal tract (62–67%) and the lung (22–27%).Case presentation: We report the case of a 36-year-old female patient diagnosed with metastatic disease, with liver, lung and lymph nodes metastasis with un...